{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:11:44Z","timestamp":1790615504751,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acquired platinum resistance poses a significant therapeutic impediment to ovarian cancer patient care, accounting for more than 200,000 deaths annually worldwide. We previously identified that overexpression of the antioxidant superoxide dismutase 1 (\n                    <jats:italic>SOD1<\/jats:italic>\n                    ) in ovarian cancer is associated with a platinum-resistant phenotype via conferring oxidative stress resistance against platinum compounds. We further demonstrated that enzymatic inhibition using small-molecule inhibitors or silencing of\n                    <jats:italic>SOD1<\/jats:italic>\n                    via RNA interference (RNAi) increased cisplatin sensitivity and potency in vitro. We launched this study to explore the potential therapeutic applications of\n                    <jats:italic>SOD1<\/jats:italic>\n                    silencing in vivo in order to reverse cisplatin resistance using a graphene-based siRNA delivery platform. PEGylated graphene oxide (GO) polyethyleneimine (GO\n                    <jats:sup>PEI<\/jats:sup>\n                    -mPEG) nanoparticle was complexed with\n                    <jats:italic>SOD1<\/jats:italic>\n                    siRNA. GO\n                    <jats:sup>PEI<\/jats:sup>\n                    -mPEG-siSOD1 exhibited high biocompatibility, siRNA loading capacity, and serum stability, and showed potent downregulation of\n                    <jats:italic>SOD1<\/jats:italic>\n                    mRNA and protein levels. We further observed that cisplatin and PEI elicited mitochondrial dysfunction and transcriptionally activated the mitochondrial unfolded protein response (UPR\n                    <jats:sup>mt<\/jats:sup>\n                    ) used as a reporter for their respective cytotoxicities.\n                    <jats:italic>SOD1<\/jats:italic>\n                    silencing was found to augment cisplatin-induced cytotoxicity resulting in considerable tumour growth inhibition in cisplatin-sensitive A2780 and cisplatin-resistant A2780\n                    <jats:sup>DDP<\/jats:sup>\n                    subcutaneous mouse xenografts. Our study highlights the potential therapeutic applicability of RNAi-mediated targeting of\n                    <jats:italic>SOD1<\/jats:italic>\n                    as a chemosensitizer for platinum-resistant ovarian cancers.\n                  <\/jats:p>","DOI":"10.1038\/s41417-023-00659-2","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T04:01:46Z","timestamp":1692072106000},"page":"1554-1568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4484-4032","authenticated-orcid":false,"given":"Attila","family":"Sz\u00e9n\u00e1si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6078-7190","authenticated-orcid":false,"given":"Enakshi","family":"Sivasudhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3584-6873","authenticated-orcid":false,"given":"Mu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"659_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","volume":"41","author":"PM Webb","year":"2017","unstructured":"Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pr Res Clin Obstet Gynaecol. 2017;41:3\u201314.","journal-title":"Best Pr Res Clin Obstet Gynaecol."},{"key":"659_CR2","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376\u201388.","journal-title":"Lancet."},{"key":"659_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0305-7372(79)80057-2","volume":"6","author":"AW Prestayko","year":"1979","unstructured":"Prestayko AW, D\u2019Aoust JC, Issell BF, Crooke ST. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 1979;6:17\u201339.","journal-title":"Cancer Treat Rev."},{"key":"659_CR4","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/S0959-8049(98)00224-X","volume":"34","author":"D Lebwohl","year":"1998","unstructured":"Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998;34:1522\u201334.","journal-title":"Eur J Cancer."},{"key":"659_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol."},{"key":"659_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/157489206777442287","volume":"1","author":"M Galanski","year":"2006","unstructured":"Galanski M. Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov. 2006;1:285\u201395.","journal-title":"Recent Pat Anticancer Drug Discov."},{"key":"659_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573\u201384.","journal-title":"Nat Rev Cancer."},{"key":"659_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0027-5107(01)00141-5","volume":"478","author":"M Kartalou","year":"2001","unstructured":"Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478:23\u201343.","journal-title":"Mutat Res."},{"key":"659_CR9","doi-asserted-by":"publisher","first-page":"1179299x1986081","DOI":"10.1177\/1179299X19860815","volume":"11","author":"R Pokhriyal","year":"2019","unstructured":"Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 2019;11:1179299x19860815.","journal-title":"Biomark Cancer."},{"key":"659_CR10","doi-asserted-by":"publisher","first-page":"R303","DOI":"10.1530\/ERC-17-0336","volume":"25","author":"B van Zyl","year":"2018","unstructured":"van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocr Relat Cancer. 2018;25:R303\u2013r18.","journal-title":"Endocr Relat Cancer."},{"key":"659_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.428","volume":"5","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.","journal-title":"Cell Death Dis."},{"key":"659_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1756-9966-30-91","volume":"30","author":"N Eckstein","year":"2011","unstructured":"Eckstein N. Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Cancer Res. 2011;30:91.","journal-title":"J Exp Clin Cancer Res."},{"key":"659_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis A, Tinker AV, Friedlander M. \u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133:624\u201331.","journal-title":"Gynecol Oncol."},{"key":"659_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-016-0278-z","volume":"9","author":"R Januchowski","year":"2016","unstructured":"Januchowski R, Sterzy\u0144ska K, Zaorska K, Sosi\u0144ska P, Klejewski A, Br\u0105zert M, et al. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016;9:65.","journal-title":"J Ovarian Res."},{"key":"659_CR15","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1021\/acs.biomac.7b00291","volume":"18","author":"C Battistella","year":"2017","unstructured":"Battistella C, Klok HA. Reversion of P-gp-mediated drug resistance in ovarian carcinoma cells with PHPMA-zosuquidar conjugates. Biomacromolecules. 2017;18:1855\u201365.","journal-title":"Biomacromolecules."},{"key":"659_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/prca.200600768","volume":"1","author":"DPG Fitzpatrick","year":"2007","unstructured":"Fitzpatrick DPG, You J-S, Bemis KG, Wery J-P, Ludwig JR, Wang M. Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC\/MS-based protein quantification method. PROTEOMICS \u2013 Clin Appl. 2007;1:246\u201363.","journal-title":"PROTEOMICS \u2013 Clin Appl."},{"key":"659_CR17","doi-asserted-by":"publisher","first-page":"108701","DOI":"10.1016\/j.abb.2020.108701","volume":"697","author":"ECA Eleutherio","year":"2021","unstructured":"Eleutherio ECA, Silva Magalh\u00e3es RS, de Ara\u00fajo Brasil A, Monteiro Neto JR, de Holanda Paranhos L. SOD1, more than just an antioxidant. Arch Biochem Biophys. 2021;697:108701.","journal-title":"Arch Biochem Biophys."},{"key":"659_CR18","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1073\/pnas.86.8.2761","volume":"86","author":"JP Phillips","year":"1989","unstructured":"Phillips JP, Campbell SD, Michaud D, Charbonneau M, Hilliker AJ. Null mutation of copper\/zinc superoxide dismutase in Drosophila confers hypersensitivity to paraquat and reduced longevity. Proc Natl Acad Sci USA. 1989;86:2761\u20135.","journal-title":"Proc Natl Acad Sci USA."},{"key":"659_CR19","doi-asserted-by":"publisher","first-page":"38966","DOI":"10.1074\/jbc.M307146200","volume":"278","author":"G Blander","year":"2003","unstructured":"Blander G, de Oliveira RM, Conboy CM, Haigis M, Guarente L. Superoxide dismutase 1 knock-down induces senescence in human fibroblasts. J Biol Chem. 2003;278:38966\u20139.","journal-title":"J Biol Chem."},{"key":"659_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02907-x","volume":"11","author":"ASM Noman","year":"2020","unstructured":"Noman ASM, Parag RR, Rashid MI, Islam S, Rahman MZ, Chowdhury AA, et al. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6\/p62 associated Nrf2-antioxidant pathway activation. Cell Death Dis. 2020;11:663.","journal-title":"Cell Death Dis."},{"key":"659_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00280-008-0791-x","volume":"63","author":"DP Brown","year":"2009","unstructured":"Brown DP, Chin-Sinex H, Nie B, Mendonca MS, Wang M. Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol. 2009;63:723\u201330.","journal-title":"Cancer Chemother Pharmacol."},{"key":"659_CR22","first-page":"2577","volume":"30","author":"JW Kim","year":"2010","unstructured":"Kim JW, Sahm H, You J, Wang M. Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells. Anticancer Res. 2010;30:2577\u201381.","journal-title":"Anticancer Res."},{"key":"659_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.addr.2016.06.011","volume":"104","author":"HJ Kim","year":"2016","unstructured":"Kim HJ, Kim A, Miyata K, Kataoka K. Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev. 2016;104:61\u201377.","journal-title":"Adv Drug Deliv Rev."},{"key":"659_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/nano7040077","volume":"7","author":"K Tatiparti","year":"2017","unstructured":"Tatiparti K, Sau S, Kashaw SK, Iyer AK. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials. 2017;7:77.","journal-title":"Nanomaterials."},{"key":"659_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijpharm.2018.05.045","volume":"546","author":"J Li","year":"2018","unstructured":"Li J, Liang H, Liu J, Wang Z. Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA\/siRNA for cancer therapy. Int J Pharm. 2018;546:215\u201325.","journal-title":"Int J Pharm."},{"key":"659_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nmat1849","volume":"6","author":"AK Geim","year":"2007","unstructured":"Geim AK, Novoselov KS. The rise of graphene. Nat Mater. 2007;6:183\u201391.","journal-title":"Nat Mater."},{"key":"659_CR27","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.2174\/13816128256661902011296290","volume":"27","author":"M Daniyal","year":"2020","unstructured":"Daniyal M, Liu B, Wang W. Comprehensive review on graphene oxide for use in drug delivery system. Curr Med Chem. 2020;27:3665\u201385.","journal-title":"Curr Med Chem."},{"key":"659_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.msec.2018.01.004","volume":"86","author":"DP Singh","year":"2018","unstructured":"Singh DP, Herrera CE, Singh B, Singh S, Singh RK, Kumar R. Graphene oxide: an efficient material and recent approach for biotechnological and biomedical applications. Mater Sci Eng C Mater Biol Appl. 2018;86:173\u201397.","journal-title":"Mater Sci Eng C Mater Biol Appl."},{"key":"659_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/smll.201001522","volume":"7","author":"L Zhang","year":"2011","unstructured":"Zhang L, Lu Z, Zhao Q, Huang J, Shen H, Zhang Z. Enhanced chemotherapy efficacy by sequential delivery of siRNA and anticancer drugs using PEI-grafted graphene oxide. Small. 2011;7:460\u20134.","journal-title":"Small."},{"key":"659_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/mt.2010.233","volume":"19","author":"AV Ulasov","year":"2011","unstructured":"Ulasov AV, Khramtsov YV, Trusov GA, Rosenkranz AA, Sverdlov ED, Sobolev AS. Properties of PEI-based polyplex nanoparticles that correlate with their transfection efficacy. Mol Ther. 2011;19:103\u201312.","journal-title":"Mol Ther."},{"key":"659_CR31","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ymthe.2017.01.024","volume":"25","author":"A Hall","year":"2017","unstructured":"Hall A, L\u00e4chelt U, Bartek J, Wagner E, Moghimi SM. Polyplex evolution: understanding biology, optimizing performance. Mol Ther. 2017;25:1476\u201390.","journal-title":"Mol Ther."},{"key":"659_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/adfm.201402762","volume":"25","author":"M Guo","year":"2015","unstructured":"Guo M, Huang J, Deng Y, Shen H, Ma Y, Zhang M, et al. pH-responsive cyanine-grafted graphene oxide for fluorescence resonance energy transfer-enhanced photothermal therapy. Adv Funct Mater. 2015;25:59\u201367.","journal-title":"Adv Funct Mater."},{"key":"659_CR33","first-page":"71","volume":"3","author":"X Rao","year":"2013","unstructured":"Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2\u02c6(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3:71\u201385.","journal-title":"Biostat Bioinforma Biomath."},{"key":"659_CR34","doi-asserted-by":"publisher","first-page":"7736","DOI":"10.1039\/c1jm10341e","volume":"21","author":"B Chen","year":"2011","unstructured":"Chen B, Liu M, Zhang L, Huang J, Yao J, Zhang Z. Polyethylenimine-functionalized graphene oxide as an efficient gene delivery vector. J Mater Chem. 2011;21:7736\u201341.","journal-title":"J Mater Chem."},{"key":"659_CR35","doi-asserted-by":"publisher","first-page":"13863","DOI":"10.1039\/C9NR02301A","volume":"11","author":"I de L\u00e1zaro","year":"2019","unstructured":"de L\u00e1zaro I, Vranic S, Marson D, Rodrigues AF, Buggio M, Esteban-Arranz A, et al. Graphene oxide as a 2D platform for complexation and intracellular delivery of siRNA. Nanoscale. 2019;11:13863\u201377.","journal-title":"Nanoscale."},{"key":"659_CR36","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","volume":"92","author":"O Boussif","year":"1995","unstructured":"Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995;92:7297\u2013301.","journal-title":"Proc Natl Acad Sci USA."},{"key":"659_CR37","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.7150\/thno.44051","volume":"10","author":"L Zhu","year":"2020","unstructured":"Zhu L, Yuan Y, Yuan L, Li L, Liu F, Liu J, et al. Activation of TFEB-mediated autophagy by trehalose attenuates mitochondrial dysfunction in cisplatin-induced acute kidney injury. Theranostics. 2020;10:5829\u201344.","journal-title":"Theranostics."},{"key":"659_CR38","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.celrep.2019.04.095","volume":"27","author":"TC Kenny","year":"2019","unstructured":"Kenny TC, Craig AJ, Villanueva A, Germain D. Mitohormesis primes tumor invasion and metastasis. Cell Rep. 2019;27:2292\u2013303.e6.","journal-title":"Cell Rep."},{"key":"659_CR39","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.1039\/C8NR00333E","volume":"10","author":"G Reina","year":"2018","unstructured":"Reina G, Chau NDQ, Nishina Y, Bianco A. Graphene oxide size and oxidation degree govern its supramolecular interactions with siRNA. Nanoscale. 2018;10:5965\u201374.","journal-title":"Nanoscale."},{"key":"659_CR40","first-page":"4183","volume":"22","author":"Y Hattori","year":"2020","unstructured":"Hattori Y, Tamaki K, Sakasai S, Ozaki KI, Onishi H. Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene\u2011silencing effects and siRNA biodistribution in mice. Mol Med Rep. 2020;22:4183\u201396.","journal-title":"Mol Med Rep."},{"key":"659_CR41","first-page":"4047","volume":"37","author":"Y Lv","year":"2021","unstructured":"Lv Y, Chen B, Chen J, Dong Y, Liu JH, Xu L. Effect of graphene oxide on the function of erythrocytes. Sheng Wu Gong Cheng Xue Bao. 2021;37:4047\u201355.","journal-title":"Sheng Wu Gong Cheng Xue Bao."},{"key":"659_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1021\/acs.bioconjchem.8b00732","volume":"30","author":"SA Smith","year":"2019","unstructured":"Smith SA, Selby LI, Johnston APR, Such GK. The endosomal escape of nanoparticles: toward more efficient cellular delivery. Bioconjug Chem. 2019;30:263\u201372.","journal-title":"Bioconjug Chem."},{"key":"659_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.toxlet.2012.12.019","volume":"218","author":"A Calarco","year":"2013","unstructured":"Calarco A, Bosetti M, Margarucci S, Fusaro L, Nicol\u00ec E, Petillo O, et al. The genotoxicity of PEI-based nanoparticles is reduced by acetylation of polyethylenimine amines in human primary cells. Toxicol Lett. 2013;218:10\u20137.","journal-title":"Toxicol Lett."},{"key":"659_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.redox.2017.11.018","volume":"15","author":"TA Tabish","year":"2018","unstructured":"Tabish TA, Zhang S, Winyard PG. Developing the next generation of graphene-based platforms for cancer therapeutics: The potential role of reactive oxygen species. Redox Biol. 2018;15:34\u201340.","journal-title":"Redox Biol."},{"key":"659_CR45","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/nano9070969","volume":"9","author":"S Gurunathan","year":"2019","unstructured":"Gurunathan S, Arsalan Iqbal M, Qasim M, Park CH, Yoo H, Hwang JH, et al. Evaluation of graphene oxide induced cellular toxicity and transcriptome analysis in human embryonic kidney cells. Nanomaterials. 2019;9:969.","journal-title":"Nanomaterials."},{"key":"659_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-016-0206-9","volume":"14","author":"MC Mendon\u00e7a","year":"2016","unstructured":"Mendon\u00e7a MC, Soares ES, de Jesus MB, Ceragioli HJ, Irazusta SP, Batista \u00c2G, et al. Reduced graphene oxide: nanotoxicological profile in rats. J Nanobiotechnology. 2016;14:53.","journal-title":"J Nanobiotechnology."},{"key":"659_CR47","doi-asserted-by":"publisher","first-page":"5851035","DOI":"10.1155\/2016\/5851035","volume":"2016","author":"A Jarosz","year":"2016","unstructured":"Jarosz A, Skoda M, Dudek I, Szukiewicz D. Oxidative stress and mitochondrial activation as the main mechanisms underlying graphene toxicity against human cancer cells. Oxid Med Cell Longev. 2016;2016:5851035.","journal-title":"Oxid Med Cell Longev."},{"key":"659_CR48","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.1158\/0008-5472.CAN-19-1395","volume":"79","author":"TC Kenny","year":"2019","unstructured":"Kenny TC, Gomez ML, Germain D. Mitohormesis, UPR(mt), and the complexity of mitochondrial DNA landscapes in cancer. Cancer Res. 2019;79:6057\u201366.","journal-title":"Cancer Res."},{"key":"659_CR49","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.biomaterials.2013.09.108","volume":"35","author":"N Chatterjee","year":"2014","unstructured":"Chatterjee N, Eom HJ, Choi J. A systems toxicology approach to the surface functionality control of graphene-cell interactions. Biomaterials. 2014;35:1109\u201327.","journal-title":"Biomaterials."},{"key":"659_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12989-016-0168-y","volume":"13","author":"L Ou","year":"2016","unstructured":"Ou L, Song B, Liang H, Liu J, Feng X, Deng B, et al. Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms. Part Fibre Toxicol. 2016;13:57.","journal-title":"Part Fibre Toxicol."}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00659-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00659-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00659-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T19:04:23Z","timestamp":1699988663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-023-00659-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1038\/s41417-023-00659-2","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"assertion":[{"value":"16 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal Study Ethics approval of this research was granted by the Ethics Committee of Xi\u2019an Jiaotong-Liverpool University. The animal study was carried out in Suzhou GenePharma with a certificate of government approved Animal Study Facility.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}